Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells

Toll-like receptor (TLR)-4 signaling promotes cytokine synthesis in vascular smooth muscle cells (VSMC). However, it is unknown how TLR-4 regulates interleukin-6 (IL-6) in VSMC. Therefore, the present study investigated cellular factors involved in TLR-4-mediated IL-6 in VSMC in terms of MAPK and tr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiovascular pharmacology 2008-01, Vol.51 (1), p.71
Hauptverfasser: Son, Yong-Hae, Jeong, Yeon-Tae, Lee, Kyeong-Ah, Choi, Kyung-Ha, Kim, Sun-Mi, Rhim, Byung-Yong, Kim, Koanhoi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page 71
container_title Journal of cardiovascular pharmacology
container_volume 51
creator Son, Yong-Hae
Jeong, Yeon-Tae
Lee, Kyeong-Ah
Choi, Kyung-Ha
Kim, Sun-Mi
Rhim, Byung-Yong
Kim, Koanhoi
description Toll-like receptor (TLR)-4 signaling promotes cytokine synthesis in vascular smooth muscle cells (VSMC). However, it is unknown how TLR-4 regulates interleukin-6 (IL-6) in VSMC. Therefore, the present study investigated cellular factors involved in TLR-4-mediated IL-6 in VSMC in terms of MAPK and transcription elements. Exposure of aortic smooth muscle cells to TLR4-specific lipopolysaccharide (LPS) not only enhanced IL-6 release but also induced IL-6 transcript via promoter activation. The promoter activation was attenuated by dominant-negative MKK1 and to a lesser extent by dominant-negative MKK3, but not by dominant-negative MKK4. IL-6 promoter activity was diminished by U0126 or SB202190, but not by SP600125. Co-transfection with dominant negative CCAAT/enhancer binding protein or with IkappaB suppressed LPS-induced promoter activation, whereas the promoter activity was not influenced by dominant negative c-Jun. Mutation in the IL-6 promoter region at the binding site of NF-kappaB or C/EBP impaired promoter activation in response to LPS. Further impairment occurred when both NF-kappaB- and C/EBP-binding sites were mutated. LPS-induced IL-6 promoter activation was also prevented by pretreatment with epigallocatechin 3-gallate, curcumin, and resveratrol. The present study reports that TLR4-agonistic LPS induces IL-6 through transcriptional activation in VSMC and ERK1/2, p38 MAPK, NF-kappaB, and C/EBP play active roles in that process.
doi_str_mv 10.1097/FJC.0b013e31815bd23d
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_18209571</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18209571</sourcerecordid><originalsourceid>FETCH-LOGICAL-p541-68e15792ea7ce7fd846360c4d97bc25867c5094477343830fff3dbb02d8b073</originalsourceid><addsrcrecordid>eNo1j9lKw0AYhedCsbX6BiLzAqn_ZNZc1mLd6kLxvswWGjvJDJlE6NtbUeHA4bs4HxyErgjMCVTyZvW0nIMBQj0linDjSupO0BSIgKJkTEzQec6fAIRxKc7QhKgSKi7JFIVNDD7jWOOXxfsz1p3Dr6tir1PSt7jpjhl8H_y4b7pCHMmNdmhih80BhybFFMMha2t3um-c_xl86WzHoHuc2xiHHW7HbIPH1oeQL9BprUP2l389Q5vV3cfyoVi_3T8uF-sicUYKoTzhsiq9ltbL2ikmqADLXCWNLbkS0nKoGJOSMqoo1HVNnTFQOmVA0hm6_pWm0bTebVPftLo_bP8_02-q81kR</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Son, Yong-Hae ; Jeong, Yeon-Tae ; Lee, Kyeong-Ah ; Choi, Kyung-Ha ; Kim, Sun-Mi ; Rhim, Byung-Yong ; Kim, Koanhoi</creator><creatorcontrib>Son, Yong-Hae ; Jeong, Yeon-Tae ; Lee, Kyeong-Ah ; Choi, Kyung-Ha ; Kim, Sun-Mi ; Rhim, Byung-Yong ; Kim, Koanhoi</creatorcontrib><description>Toll-like receptor (TLR)-4 signaling promotes cytokine synthesis in vascular smooth muscle cells (VSMC). However, it is unknown how TLR-4 regulates interleukin-6 (IL-6) in VSMC. Therefore, the present study investigated cellular factors involved in TLR-4-mediated IL-6 in VSMC in terms of MAPK and transcription elements. Exposure of aortic smooth muscle cells to TLR4-specific lipopolysaccharide (LPS) not only enhanced IL-6 release but also induced IL-6 transcript via promoter activation. The promoter activation was attenuated by dominant-negative MKK1 and to a lesser extent by dominant-negative MKK3, but not by dominant-negative MKK4. IL-6 promoter activity was diminished by U0126 or SB202190, but not by SP600125. Co-transfection with dominant negative CCAAT/enhancer binding protein or with IkappaB suppressed LPS-induced promoter activation, whereas the promoter activity was not influenced by dominant negative c-Jun. Mutation in the IL-6 promoter region at the binding site of NF-kappaB or C/EBP impaired promoter activation in response to LPS. Further impairment occurred when both NF-kappaB- and C/EBP-binding sites were mutated. LPS-induced IL-6 promoter activation was also prevented by pretreatment with epigallocatechin 3-gallate, curcumin, and resveratrol. The present study reports that TLR4-agonistic LPS induces IL-6 through transcriptional activation in VSMC and ERK1/2, p38 MAPK, NF-kappaB, and C/EBP play active roles in that process.</description><identifier>ISSN: 0160-2446</identifier><identifier>DOI: 10.1097/FJC.0b013e31815bd23d</identifier><identifier>PMID: 18209571</identifier><language>eng</language><publisher>United States</publisher><subject>Aorta - cytology ; Aorta - metabolism ; CCAAT-Enhancer-Binding Proteins - metabolism ; Cells, Cultured ; Humans ; Interleukin-6 - metabolism ; Lipopolysaccharides - toxicity ; Mitogen-Activated Protein Kinase 1 - metabolism ; Mitogen-Activated Protein Kinase 3 - metabolism ; Mitogen-Activated Protein Kinases - metabolism ; Muscle, Smooth, Vascular - cytology ; Muscle, Smooth, Vascular - metabolism ; NF-kappa B - metabolism ; p38 Mitogen-Activated Protein Kinases - metabolism ; Signal Transduction ; Toll-Like Receptor 4 - metabolism ; Transcription, Genetic</subject><ispartof>Journal of cardiovascular pharmacology, 2008-01, Vol.51 (1), p.71</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18209571$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Son, Yong-Hae</creatorcontrib><creatorcontrib>Jeong, Yeon-Tae</creatorcontrib><creatorcontrib>Lee, Kyeong-Ah</creatorcontrib><creatorcontrib>Choi, Kyung-Ha</creatorcontrib><creatorcontrib>Kim, Sun-Mi</creatorcontrib><creatorcontrib>Rhim, Byung-Yong</creatorcontrib><creatorcontrib>Kim, Koanhoi</creatorcontrib><title>Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells</title><title>Journal of cardiovascular pharmacology</title><addtitle>J Cardiovasc Pharmacol</addtitle><description>Toll-like receptor (TLR)-4 signaling promotes cytokine synthesis in vascular smooth muscle cells (VSMC). However, it is unknown how TLR-4 regulates interleukin-6 (IL-6) in VSMC. Therefore, the present study investigated cellular factors involved in TLR-4-mediated IL-6 in VSMC in terms of MAPK and transcription elements. Exposure of aortic smooth muscle cells to TLR4-specific lipopolysaccharide (LPS) not only enhanced IL-6 release but also induced IL-6 transcript via promoter activation. The promoter activation was attenuated by dominant-negative MKK1 and to a lesser extent by dominant-negative MKK3, but not by dominant-negative MKK4. IL-6 promoter activity was diminished by U0126 or SB202190, but not by SP600125. Co-transfection with dominant negative CCAAT/enhancer binding protein or with IkappaB suppressed LPS-induced promoter activation, whereas the promoter activity was not influenced by dominant negative c-Jun. Mutation in the IL-6 promoter region at the binding site of NF-kappaB or C/EBP impaired promoter activation in response to LPS. Further impairment occurred when both NF-kappaB- and C/EBP-binding sites were mutated. LPS-induced IL-6 promoter activation was also prevented by pretreatment with epigallocatechin 3-gallate, curcumin, and resveratrol. The present study reports that TLR4-agonistic LPS induces IL-6 through transcriptional activation in VSMC and ERK1/2, p38 MAPK, NF-kappaB, and C/EBP play active roles in that process.</description><subject>Aorta - cytology</subject><subject>Aorta - metabolism</subject><subject>CCAAT-Enhancer-Binding Proteins - metabolism</subject><subject>Cells, Cultured</subject><subject>Humans</subject><subject>Interleukin-6 - metabolism</subject><subject>Lipopolysaccharides - toxicity</subject><subject>Mitogen-Activated Protein Kinase 1 - metabolism</subject><subject>Mitogen-Activated Protein Kinase 3 - metabolism</subject><subject>Mitogen-Activated Protein Kinases - metabolism</subject><subject>Muscle, Smooth, Vascular - cytology</subject><subject>Muscle, Smooth, Vascular - metabolism</subject><subject>NF-kappa B - metabolism</subject><subject>p38 Mitogen-Activated Protein Kinases - metabolism</subject><subject>Signal Transduction</subject><subject>Toll-Like Receptor 4 - metabolism</subject><subject>Transcription, Genetic</subject><issn>0160-2446</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j9lKw0AYhedCsbX6BiLzAqn_ZNZc1mLd6kLxvswWGjvJDJlE6NtbUeHA4bs4HxyErgjMCVTyZvW0nIMBQj0linDjSupO0BSIgKJkTEzQec6fAIRxKc7QhKgSKi7JFIVNDD7jWOOXxfsz1p3Dr6tir1PSt7jpjhl8H_y4b7pCHMmNdmhih80BhybFFMMha2t3um-c_xl86WzHoHuc2xiHHW7HbIPH1oeQL9BprUP2l389Q5vV3cfyoVi_3T8uF-sicUYKoTzhsiq9ltbL2ikmqADLXCWNLbkS0nKoGJOSMqoo1HVNnTFQOmVA0hm6_pWm0bTebVPftLo_bP8_02-q81kR</recordid><startdate>200801</startdate><enddate>200801</enddate><creator>Son, Yong-Hae</creator><creator>Jeong, Yeon-Tae</creator><creator>Lee, Kyeong-Ah</creator><creator>Choi, Kyung-Ha</creator><creator>Kim, Sun-Mi</creator><creator>Rhim, Byung-Yong</creator><creator>Kim, Koanhoi</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200801</creationdate><title>Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells</title><author>Son, Yong-Hae ; Jeong, Yeon-Tae ; Lee, Kyeong-Ah ; Choi, Kyung-Ha ; Kim, Sun-Mi ; Rhim, Byung-Yong ; Kim, Koanhoi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p541-68e15792ea7ce7fd846360c4d97bc25867c5094477343830fff3dbb02d8b073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aorta - cytology</topic><topic>Aorta - metabolism</topic><topic>CCAAT-Enhancer-Binding Proteins - metabolism</topic><topic>Cells, Cultured</topic><topic>Humans</topic><topic>Interleukin-6 - metabolism</topic><topic>Lipopolysaccharides - toxicity</topic><topic>Mitogen-Activated Protein Kinase 1 - metabolism</topic><topic>Mitogen-Activated Protein Kinase 3 - metabolism</topic><topic>Mitogen-Activated Protein Kinases - metabolism</topic><topic>Muscle, Smooth, Vascular - cytology</topic><topic>Muscle, Smooth, Vascular - metabolism</topic><topic>NF-kappa B - metabolism</topic><topic>p38 Mitogen-Activated Protein Kinases - metabolism</topic><topic>Signal Transduction</topic><topic>Toll-Like Receptor 4 - metabolism</topic><topic>Transcription, Genetic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Son, Yong-Hae</creatorcontrib><creatorcontrib>Jeong, Yeon-Tae</creatorcontrib><creatorcontrib>Lee, Kyeong-Ah</creatorcontrib><creatorcontrib>Choi, Kyung-Ha</creatorcontrib><creatorcontrib>Kim, Sun-Mi</creatorcontrib><creatorcontrib>Rhim, Byung-Yong</creatorcontrib><creatorcontrib>Kim, Koanhoi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Journal of cardiovascular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Son, Yong-Hae</au><au>Jeong, Yeon-Tae</au><au>Lee, Kyeong-Ah</au><au>Choi, Kyung-Ha</au><au>Kim, Sun-Mi</au><au>Rhim, Byung-Yong</au><au>Kim, Koanhoi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells</atitle><jtitle>Journal of cardiovascular pharmacology</jtitle><addtitle>J Cardiovasc Pharmacol</addtitle><date>2008-01</date><risdate>2008</risdate><volume>51</volume><issue>1</issue><spage>71</spage><pages>71-</pages><issn>0160-2446</issn><abstract>Toll-like receptor (TLR)-4 signaling promotes cytokine synthesis in vascular smooth muscle cells (VSMC). However, it is unknown how TLR-4 regulates interleukin-6 (IL-6) in VSMC. Therefore, the present study investigated cellular factors involved in TLR-4-mediated IL-6 in VSMC in terms of MAPK and transcription elements. Exposure of aortic smooth muscle cells to TLR4-specific lipopolysaccharide (LPS) not only enhanced IL-6 release but also induced IL-6 transcript via promoter activation. The promoter activation was attenuated by dominant-negative MKK1 and to a lesser extent by dominant-negative MKK3, but not by dominant-negative MKK4. IL-6 promoter activity was diminished by U0126 or SB202190, but not by SP600125. Co-transfection with dominant negative CCAAT/enhancer binding protein or with IkappaB suppressed LPS-induced promoter activation, whereas the promoter activity was not influenced by dominant negative c-Jun. Mutation in the IL-6 promoter region at the binding site of NF-kappaB or C/EBP impaired promoter activation in response to LPS. Further impairment occurred when both NF-kappaB- and C/EBP-binding sites were mutated. LPS-induced IL-6 promoter activation was also prevented by pretreatment with epigallocatechin 3-gallate, curcumin, and resveratrol. The present study reports that TLR4-agonistic LPS induces IL-6 through transcriptional activation in VSMC and ERK1/2, p38 MAPK, NF-kappaB, and C/EBP play active roles in that process.</abstract><cop>United States</cop><pmid>18209571</pmid><doi>10.1097/FJC.0b013e31815bd23d</doi></addata></record>
fulltext fulltext
identifier ISSN: 0160-2446
ispartof Journal of cardiovascular pharmacology, 2008-01, Vol.51 (1), p.71
issn 0160-2446
language eng
recordid cdi_pubmed_primary_18209571
source MEDLINE; Journals@Ovid LWW Legacy Archive; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals
subjects Aorta - cytology
Aorta - metabolism
CCAAT-Enhancer-Binding Proteins - metabolism
Cells, Cultured
Humans
Interleukin-6 - metabolism
Lipopolysaccharides - toxicity
Mitogen-Activated Protein Kinase 1 - metabolism
Mitogen-Activated Protein Kinase 3 - metabolism
Mitogen-Activated Protein Kinases - metabolism
Muscle, Smooth, Vascular - cytology
Muscle, Smooth, Vascular - metabolism
NF-kappa B - metabolism
p38 Mitogen-Activated Protein Kinases - metabolism
Signal Transduction
Toll-Like Receptor 4 - metabolism
Transcription, Genetic
title Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T12%3A54%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Roles%20of%20MAPK%20and%20NF-kappaB%20in%20interleukin-6%20induction%20by%20lipopolysaccharide%20in%20vascular%20smooth%20muscle%20cells&rft.jtitle=Journal%20of%20cardiovascular%20pharmacology&rft.au=Son,%20Yong-Hae&rft.date=2008-01&rft.volume=51&rft.issue=1&rft.spage=71&rft.pages=71-&rft.issn=0160-2446&rft_id=info:doi/10.1097/FJC.0b013e31815bd23d&rft_dat=%3Cpubmed%3E18209571%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18209571&rfr_iscdi=true